Pharmaxis touts progress in cystic fibrosis study
Monday, 19 December, 2005
Sydney-based drug developer Pharmaxis (ASX:PXS, Nasdaq:PXSL) has begun the dosing phase of its phase II clinical trial in patients with cystic fibrosis.
The study, which aims to determine the benefits of Bronchitol in children also receiving the market leading treatment, rhDNase, is being conducted at two sites in the UK.
The 42 patients enrolled in the study will receive three months treatment with each of three different therapies -- Bronchitol alone, both Bronchitol and rhDNase together and rhDNase alone. The trial will measure changes in lung function, airway inflammation, infections, and quality of life.
Full patient recruitment is expected to take about eight months
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
